Omrix Biopharmaceuticals Inc.

Ethicon, Gmbh

Depuy Synthes Products, Inc.

Opperbas Holding B.v.

Kamada Ltd.

Liliana Bar

Israel Nur

Roberto Meidler

Oleg Belyaev

Eyal Sheetrit

Guy Tomer

Sridevi N Dhanaraj

Erez Ilan

Anne J Gorman

Malkit Azachi

Anthony J Kihm

Charito S Buensuceso

Orgad Laub

Roee Atlas

Moshe Baru

Roni Mintz

Edna Bechor

Guanghui Zhang

Ashley DeAnglis

Sanyog Manohar Pendharkar

Moti Meron

Lior Weissman

Kfir Regev

Nina Raver-Shapira

Nachum Yonah

Ayelet Cooper

Ashley De Anglis

Charito Buensuceso

Meidler Roberto

Provided are methods for lyophilization of an aqueous thrombin solution, thrombin solutions for use in such lyophilization methods, and solid thrombin compositions produced by such methods.

Thrombin solution and methods of use thereof

The present invention provides compositions and methods for improving wound healing, reducing scar formation and/or promoting skin health and aesthetic appearance. In particular, the present invention provides protein compositions that are derived from Cohn fraction IV and/or IV-1 useful in promoting wound healing and for cosmetic care of the skin.

Compositions derived from Cohn fraction paste and use thereof

The invention relates to a prosthetic for repairing an opening or a defect in a soft tissue, to its preparation and use. The prosthetic of the invention comprises a substrate viscerally-coated with stabilized and non-completely dry fibrin. The prosthetic displays reduced postoperative complications following its implantation.

Implantable device comprising a substrate pre-coated with stabilized fibrin

A method is described for the measurement of thrombin activity in the presence of fibrinogen, or for the measurement of the functionality of fibrinogen in the presence of thrombin.

Protein assay

The invention relates to an immunoglobulin composition reduced in thrombogenic agents and to methods for its preparation. One method comprises subjecting an immunoglobulin containing solution to a negative cation exchanger chromatography at a pH in the range of higher than 3.8 to equal to or lower than 5.3. The solution can also be subjected to a negative anion exchanger chromatography at a pH in the range of 7 to 8.2.

Immunoglobulin reduced in thrombogenic agents and preparation thereof

Compositions and methods of using cells derived from umbilical cord tissue, to stimulate and support angiogenesis, to improve blood flow, to regenerate, repair, and improve skeletal muscle damaged by a peripheral ischemic event, and to protect skeletal muscle from ischemic damage in peripheral vascular disease patients are disclosed. In particular, methods of treating a patient having a peripheral vascular disease by systemic administration of umbilical derived cells are disclosed.

Treatment of peripheral vascular disease using umbilical cord tissue-derived cells

The present invention is directed to a reinforced absorbable multilayered hemostatic wound dressing comprising a first absorbable nonwoven fabric, a second absorbable woven or knitted fabric, thrombin and/or fibrinogen.

Reinforced absorbable multilayered hemostatis wound dressing

The present invention is directed to a method for manufacturing a cross-linked gelatin sponge having a surface by providing a cross-linked gelatin sponge, wetting the surface of the sponge by applying a sufficient amount of liquid comprising a protein or peptide active ingredient, wherein a sufficient amount of liquid is one that retains the flexibility of the sponge even after drying. The sponge is then dried the sponge to obtain a flexible, dry and ready to use cross linked gelatin sponge having a layer of protein or peptide active ingredient on the surface thereof.

Gelatin sponge comprising an active ingredient, its preparation and use

A concentrated, immunoglobulin composition for treating subjects vaccinated against or infected with a pathogenic microorganism, is made by (a) selecting a population of individuals previously vaccinated against antigens associated with the pathogenic microorganism; (b) identifying very high titer individuals by determining the level of specific antibodies immunoreactive with the pathogenic microorganism in the blood of the individuals; (c) combining blood from the very high titer individuals; and (d) purifying and/or concentrating the product of step (c). A concentrated immunoglobulin composition can include specific antibodies immunoreactive with a pathogenic microorganism, wherein the titer of specific antibodies is at least 5 times higher than the average titer of specific antibodies of a population of individuals previously vaccinated against antigens associated with the pathogenic microorganism. The composition has a relatively high protein concentration and a low percentage of protein aggregates. The pathogenic microorganism is preferably smallpox virus or vaccinia virus.

Intravenous immunoglobulin composition

The invention relates to the use of viral inactivated-plasma cryoprecipitate concentrate (VIPCC) comprising a suitable fibronactin/fibrinogen ratio for treating a spine disease, disorder or condition such as intervertebral disc degeneration.

Compositions suitable for treatment of spinal disease, disorder or condition

The invention relates to purification of an intact, non-degraded macromolecule from a biological mixture comprising the macromolecule in the presence of its lytic enzyme. The method comprises providing the biological mixture as a heterogeneous mixture comprising the lytic enzyme, at least partially, in soluble form and the macromolecule, at least partially, in non-soluble form; batch-wise contacting the heterogeneous mixture with an immobilized inhibitor of the lytic enzyme; increasing the solubility of the macromolecule in the mixture; and removing the immobilized inhibitor from the mixture.

Method for removing a lytic enzyme from a heterogeneous mixture

Growing community of inventors

Rehovot, Israel

Liliana Bar